Amycretin: Novo Nordisk’s GLP-1 and Amylin Drug in Trials
Amycretin is Novo Nordisk's investigational GLP-1 and amylin drug, tested as a weekly shot and a daily pill. Trial results and phase 3 status.
Read MoreAmycretin is Novo Nordisk's investigational GLP-1 and amylin drug, tested as a weekly shot and a daily pill. Trial results and phase 3 status.
Read MoreMariTide is Amgen's investigational once-monthly obesity shot. What it is, phase 2 results, side effects and the MARITIME phase 3 trials.
Read MoreIs semaglutide the same as Ozempic? Ozempic is one brand of semaglutide. How it differs from Wegovy, Rybelsus and compounded or salt forms.
Read MoreIs there a Victoza generic? Yes. Who makes FDA-approved liraglutide generics for Victoza and Saxenda, what AP ratings mean and what stays the same.
Read MoreIs there an Ozempic generic? What FDA records show about generic semaglutide, patent dates, Canada and India approvals, and compounded copies.
Read MoreA GLP-1 drugs list for 2026: every FDA-approved brand, its active ingredient, form, approved uses and approval year, plus generics and discontinued drugs.
Read MoreGLP-1 Alzheimer's research explained: why semaglutide was tested, what the EVOKE trials found and how to read dementia studies.
Read MoreOzempic for PCOS explained: why it is off-label, what the 2023 PCOS guideline says about GLP-1 drugs, what small trials found and pregnancy cautions.
Read MoreOzempic blindness explained: what NAION studies found, what EU and U.S. labels say, the retinopathy warning and when vision changes are urgent.
Read MoreZepbound sleep apnea facts: the December 2024 FDA approval, SURMOUNT-OSA results, why CPAP still matters and how other GLP-1 drugs compare.
Read More